Plain-English translation of NCT04123314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a small pilot study testing whether — a naturally occurring psychedelic compound — can safely reduce depression in people who have been diagnosed with early-stage Alzheimer's disease or mild cognitive impairment. You would receive two supervised doses of the medication over 8 weeks, along with weekly psychological support. The study will track whether the treatment improves your mood and quality of life.
Depression is common in people with early memory loss, but standard antidepressants don't always work well for this group. This medication is being tested as a possible new option to help reduce depression and improve wellbeing in these patients.
You likely qualify if…
You likely don't qualify if…
You would participate in an 8-week program that includes weekly one-on-one psychological support sessions. During weeks 4 and 6, you would receive two supervised doses of the medication in a controlled medical setting. After your final dose, you would return for follow-up visits over the next 6 months so researchers can measure whether your mood and quality of life have improved.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States